Hutchmed (China) Limited American Depositary Shares (HCM)
Top Wall Street Forecasters Revamp Paycor HCM Price Expectations Ahead Of Q4 Earnings
Paycor HCM, Inc. PYCR is expected to release earnings results for its fourth quarter, after the closing bell on Wednesday, Aug. 14.
Hutchmed Growing Sales By 64% In H1 2024
Share price up nearly 20% since our previous Buy call. Approval of the colon cancer drug FRUZAQLA by the U.S. FDA was a game-changer to their growth in sales. We expect continued growth in sales of oncology products from the approval of FRUZAQLA in the E.U. and Japan.
HUTCHMED (China) Limited (HCM) Q2 2024 Earnings Call Transcript
HUTCHMED (China) Limited (NASDAQ:HCM ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants David Ng - Head:Investor Relations Wei-Guo Su - Chief Executive Officer & Chief Scientific Officer Johnny Cheng - Chief Financial Officer George Yuan - Head of Commercial Michael Shi - Executive Vice President, Head of R&D & Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Chen Chen - UBS Clara Dong - Jefferies Adam McCarter - Cavendish Paul Choi - Goldman Sachs Julie Simmonds - Panmure Liberum David Ng Hello, everyone. Welcome to HUTCHMED 2014 Interim Results Presentation.
Paycom: Initiating Buy On Strong Growth Tailwind And BETI Pricing Power
Paycom is recommended as a buy due to its long-term growth potential and strong value proposition with its BETI product. The global HCM software industry is expected to grow, providing opportunities for cloud-based HCM solutions like PAYC. The revised sales strategy and international expansion are expected to drive customer satisfaction and future growth for PAYC.
